TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32045501
Drug: High-dose baclofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose baclofen (75 mg/day)
Study: 32045501
Drug: Low-dose baclofen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose baclofen (30 mg/day)
Study: 36243123
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline injections
Study: 36379883
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA) 1g before incision, followed by 125mg/h infusion
Study: 34448219
Drug: Single 6-mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 6-mm implant with a cantilever (ONE-C)
Study: 34448219
Drug: Two 6-mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 6-mm implants (TWO)
Study: 35932397
Drug: SHUTi-OASIS (Internet-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHUTi-OASIS (Internet-delivered cognitive behavioral therapy for insomnia)
Study: 32959588
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D calcium chewable tablets (0.6 g, once a day) and calcitriol capsules (0.25 μg, three times a day)
Study: 33141616
Drug: CEE (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE (oral conjugated equine estrogens)
Study: 33141616
Drug: CEE+MPA (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE+MPA (oral conjugated equine estrogens and medroxyprogesterone acetate)
Study: 34297008
Drug: Behavioral hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral hypnotic suggestibility
Study: 36115667
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment with gentamicin (80 mg), vancomycin (1 g), and cefazolin (1 g) dissolved in 500 mL of isotonic saline.
Study: 36115667
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution of 500 mL isotonic saline.
Study: 36115667
Drug: Local treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local treatment with gentamicin, vancomycin, and cefazolin.
Study: 36115667
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution of isotonic saline.
Study: 33452045
Drug: CSCI-furosemide (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSCI-furosemide (average daily dose 125 mg, duration 10 days)
Study: 32647367
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g whole flaxseed powder
Study: 32647367
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g hesperidin supplementation
Study: 32647367
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g flaxseed and 1 g hesperidin (flax‐hes)
Study: 34246238
Drug: Functional disabilities
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional disabilities in instrumental activities of daily living, self-care activities, and functional mobility
Study: 32991429
Drug: TPF-based induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: TPF-based induction chemotherapy (IC) regimen
Study: 32991429
Drug: TP-based induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: TP-based induction chemotherapy (IC) regimen
Study: 32991429
Drug: GP-based induction
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP-based induction chemotherapy (IC) regimen
Study: 33355063
Drug: Unified protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified protocol for the transdiagnostic treatment of emotional disorders (UP)
Study: 36425571
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg Nigella sativa (450 mg soft gelatin capsules twice daily for two weeks)
Study: 36425571
Drug: 2,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 IU of vitamin D3 (1000-IU tablets, two tablets once daily)
Study: 36425571
Drug: 900 mg
Normalized name: diosmin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg Nigella sativa and 2,000 IU of vitamin D3 (same dosing as previous groups)
Study: 36425571
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Nigella sativa and vitamin D3
Study: 33129356
Drug: Unified protocol
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unified protocol for the transdiagnostic treatment of emotional disorders (n = 35)
Study: 35279873
Drug: GTCs 540
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTCs 540 mg plus vitamin C 50 mg
Study: 35704329
Drug: Licaminlimab (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licaminlimab (60 mg/mL, 8 drops/day for 15 days, 4 drops/day for 7 days, then matching vehicle for 7 days)
Study: 35704329
Drug: Dexamethasone eye
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone eye drops (8 drops/day for 15 days, tapering to 1 drop/day over 14 days)
Study: 35871917
Drug: Probiotic yogurt
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic yogurt (100 g daily for 6 weeks)
Study: 35871917
Drug: Ordinary yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ordinary yogurt (100 g daily for 6 weeks)
Study: 32918323
Drug: zolpidem extended-release
Normalized name: zolpidem Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: zolpidem extended-release (ER)
Study: 32711599
Drug: Nanosilver nasal
Normalized name: Nanosilver
DrugBank: Silver (DB12965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nanosilver nasal spray post-surgery
Study: 32725352
Drug: 0.2% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% bupivacaine infusion via mcTAP catheters
Study: 32725352
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion via mcTAP catheters (Control)
Study: 33481452
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia injection followed by ULB in the right eyelid and then in the left (Group A)
Study: 33481452
Drug: Local anesthesia
Normalized name: Esters of benzoic acid for local anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local anesthesia injection to both eyelids followed by ULB on both eyelids (Group B)
Study: 32358782
Drug: HRV biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRV biofeedback (HRVB) training, 4-6 weekly sessions until skill acquisition
Study: 33437991
Drug: Cognitive Stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Stimulation Therapy (CST-IT)
Study: 34148297
Drug: Test cefradine
Normalized name: cefradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test cefradine capsules (250 mg single dose) under fasting conditions
Study: 34148297
Drug: Reference cefradine
Normalized name: cefradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference cefradine capsules (250 mg single dose) under fasting conditions
Study: 34148297
Drug: Test cefradine
Normalized name: cefradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test cefradine capsules (250 mg single dose) under fed conditions
Study: 34148297
Drug: Reference cefradine
Normalized name: cefradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reference cefradine capsules (250 mg single dose) under fed conditions
Study: 32054486
Drug: TFD containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFD containing 140 mg of caffeine
Study: 32054486
Drug: TFD containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: TFD containing 100 mg of caffeine
Study: 34757657
Drug: Ensartinib (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensartinib (225 mg) after a high-fat, high-calorie meal
Study: 32826409
Drug: Maternal-administered NICU-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal-administered NICU-based bundle of interventions
Study: 33413104
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 15 ml (0.25%) ropivacaine on each side
Study: 34942136
Drug: Risdiplam (5.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risdiplam (5.00 mg for individuals ≥20 kg or 0.25 mg/kg for individuals <20 kg)
Study: 32094459
Drug: PM2.5 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: PM2.5 (10 µg/m3 increase in 3-day moving average, lag 0-2)
Study: 37365436
Drug: Relugolix plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix plus E2 1 mg and NETA 0.5 mg
Study: 37365436
Drug: Relugolix 40
Normalized name: relugolix 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix 40 mg alone
Study: 34410234
Drug: Thoracic spine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic spine manipulation along with conventional physical therapy
Study: 32824394
Drug: Virtual Reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual Reality (VR) treatment group
Study: 34913256
Drug: Negative attitude
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Negative attitude to treatment
Study: 33057725
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg BID or 10 mg BID
Study: 35906623
Drug: 61.2 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 61.2 Gy radiation dose with concurrent chemoradiotherapy (paclitaxel/cisplatin regimen for 2 cycles followed by consolidation chemotherapy for 2 cycles)
Study: 35906623
Drug: 50.4 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50.4 Gy radiation dose with concurrent chemoradiotherapy (paclitaxel/cisplatin regimen for 2 cycles followed by consolidation chemotherapy for 2 cycles)
Study: 32246153
Drug: Spaced formats
Normalized name: formate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spaced formats of Prolonged Exposure (PE) or Present Centered Therapy
Study: 32667286
Drug: Selgantolimod 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selgantolimod 0.5 mg
Study: 32667286
Drug: Selgantolimod 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selgantolimod 1.5 mg
Study: 32667286
Drug: Selgantolimod 3
Normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selgantolimod 3 mg
Study: 32667286
Drug: Selgantolimod 5
Normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selgantolimod 5 mg
Study: 33275318
Drug: Imeglimin 1000
Normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Imeglimin 1000 mg
Study: 32275365
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) at governor vessel combined with donepezil hydrochloride (5 mg/day, increased to 10 mg/day after 4 weeks if needed) for 8 weeks.
Study: 32275365
Drug: Donepezil hydrochloride
Normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Donepezil hydrochloride alone (5 mg/day, increased to 10 mg/day after 4 weeks if needed) for 8 weeks.
Study: 34580704
Drug: Antibiotics while
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics while waiting for surgery
Study: 34580704
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics while waiting for surgery
Study: 35645167
Drug: as-needed budesonide-formoterol
Normalized name: budesonide / formoterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: as-needed budesonide-formoterol (BFM) (160/4.5 μg)
Study: 35645167
Drug: budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide (BUD) (200 μg) twice daily
Study: 32079739
Drug: Ultrasound-guided rhomboid
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided rhomboid intercostal block with 30 mL 0.25% bupivacaine
Study: 33478482
Drug: Curcumin extract
Normalized name: Curcumin Extract 300 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin extract (Curcugen™) 500 mg once daily for 8 weeks
Study: 33245858
Drug: Prednisone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (100 mg oral for 5 days, tapering 20 mg every 3 days for a total of 17 days)
Study: 36114520
Drug: Cognitive Enhancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Enhancement Therapy
Study: 32776664
Drug: Endovascular therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular therapy (EVT) for AIS
Study: 32424376
Drug: Method A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method A (presoaking in 1% sodium dodecyl sulfate followed by ultrasonication with 4 mol/L guanidine hydrochloride)
Study: 32424376
Drug: Method B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Method B (soaking in distilled water followed by ultrasonication with 4 mol/L guanidine hydrochloride)
Study: 36127097
Drug: Abdominal CT
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal CT scanning following thoracic low-dose CT (LDCT) for lung cancer screening
Study: 32570654
Drug: e-Prescription systems
Approvals — FDA: no, EMA: no, PMDA: no
Description: e-Prescription systems
Study: 34467834
Drug: Resveratrol 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 1000 mg daily for 3 months
Study: 38879571
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 12 weeks
Study: 35857241
Drug: Synbiotics (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synbiotics (1 g containing both pre- and probiotics administered twice a day for 14 days)
Study: 32619715
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using methylene blue mediated gallium aluminum arsenide laser at 635 nm, 6.5 J/cm2 for 10 seconds at 10 points, applied immediately after first wire and at days 3, 7, 14 of the first month, repeated for additional 2 months.
Study: 36126327
Drug: STRT+Leu (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: STRT+Leu (16 g of protein containing ∼3 g of leucine)
Study: 33921737
Drug: Fitness training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fitness training protocol consisting of three weekly sessions lasting 90 min
Study: 32413530
Drug: Beetroot-containing placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot-containing placebo capsules
Study: 33990958
Drug: Mean arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean arterial pressure (MAP) of 60 mm Hg using norepinephrine (NE) infusion
Study: 33990958
Drug: Mean arterial
Normalized name: Echinacea, aerial parts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean arterial pressure (MAP) of 90 mm Hg using norepinephrine (NE) infusion
Study: 33813359
Drug: levodopa +
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: levodopa + donepezil (5 mg)
Study: 36548296
Drug: MAP goal
Normalized name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 6 g in 100 g / PADIMATE O 8 g in 100 g TOPICAL LIPSTICK [Goofy Sun Smacker SPF 24 Berry Goal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAP goal of 65 to 85 mmHg (L group)
Study: 35063002
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese medicine collaborative model (TCMCM) combined with usual adjuvant chemotherapy
Study: 35063002
Drug: Usual adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual adjuvant chemotherapy
Study: 36078940
Drug: Ultrasound (US)
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US) therapy
Study: 36006698
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment‐as‐usual)
Study: 34062937
Drug: Oat β-Glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat β-Glucan (1 g OBG, n = 104)
Study: 34062937
Drug: Oat β-Glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat β-Glucan (1 g OBG)
Study: 35560850
Drug: All dietary
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All dietary treatments (10%, 15%, 20%, 25%, 30% kcal carbohydrate)
Study: 34180414
Drug: PLIÉ intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PLIÉ intervention (twice weekly classes for 12 weeks)
Study: 35733098
Drug: Conventional speech
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional speech therapy + functional electrotherapy
Study: 37282797
Drug: Conventional speech
Normalized name: TRACH TUBE,SPEECH SZ 10 BLOM #313-30-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional speech therapy
Study: 36341216
Drug: 25, 75,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25, 75, 150, 300, 450, or 600 mg tafolecimab subcutaneously, 75 or 450 mg intravenously
Study: 36341216
Drug: 75 or
Normalized name: Stalevo 75 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 or 140 mg tafolecimab every 2 weeks, 300 or 420 mg every 4 weeks, or 450 or 600 mg every 6 weeks subcutaneously
Study: 36341216
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of tafolecimab
Study: 33039478
Drug: Allergen-specific immunotherapy
Normalized name: Pacific halibut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen-specific immunotherapy (AIT) with allergoids to birch and/or grass
Study: 32381080
Drug: Observation without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Observation without treatment
Study: 33682648
Drug: Continuation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation with sertraline (50 mg/day)
Study: 33682648
Drug: Continuation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation with sertraline (100 mg/day)
Study: 33682648
Drug: Optimized treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized treatment (individualized treatment rule)
Study: 33682648
Drug: Combining mirtazapine
Normalized name: Mirtazapine
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combining mirtazapine with sertraline
Study: 36539949
Drug: Standard pharmaceutical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmaceutical care (Control)
Study: 34998427
Drug: Fluralaner (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluralaner (oral administration at the approved dose on day 0)
Study: 33956987
Drug: VPM-DBS in
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: VPM-DBS in combination with lateral CM stimulation
Study: 34289755
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 14 mg at steady-state with levothyroxine (600 μg single-dose)
Study: 34289755
Drug: SNAC 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNAC 300 mg with levothyroxine (600 μg single-dose)
Study: 34289755
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 14 mg at steady-state with five placebo tablets
Study: 34289755
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide 14 mg at steady-state alone
Study: 32723352
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate mucoadhesive tablet
Study: 37650236
Drug: Bamlanivimab 700
Normalized name: bamlanivimab 700 MG in 20 mL Injection (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamlanivimab 700 mg
Study: 33475701
Drug: Bamlanivimab 2800
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab 2800 mg
Study: 34981077
Drug: Bamlanivimab 7000
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab 7000 mg
Study: 33475701
Drug: Bamlanivimab and
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bamlanivimab and Etesevimab (2800 mg each)
Study: 33836708
Drug: Individually targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individually targeted human milk fortification with protein and fat modulars based on daily point‐of‐care milk analysis.
Study: 35380713
Drug: Cetuximab 500
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 500 mg/m2, bevacizumab 5 mg/kg, and irinotecan 180 mg/m2 (CBI)
Study: 32772304
Drug: Pharmacists reviewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists reviewing medication orders
Study: 32772304
Drug: Pharmacists monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacists monitoring patients' response to therapy and adverse drug effects
Study: 32772304
Drug: Collaboration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaboration with pharmacists in developing treatment plans
Study: 34825307
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (5 years treatment)
Study: 34798826
Drug: Pharmacist-led, deprescribing-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led, deprescribing-focused medication review, followed by an individualised treatment modification plan.
Study: 35974369
Drug: Exp I:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exp I: active and passive activity training (APAT) + NMES treatment on the gastrocnemius and tibialis anterior muscle
Study: 35974369
Drug: Exp II:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exp II: APAT + NMES treatment on gastrocnemius alone
Study: 32460565
Drug: Calendula ointment
Normalized name: CALENDULA
DrugBank: Calendula officinalis whole (DB14315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calendula ointment